Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Approves Lenvima/Keytruda Pair, Opdivo Label Expansion
December 27, 2021
- Payer, Healthcare Reps Call for Stable Supply Measures for Achieving New Generic Share Target: Chuikyo
December 27, 2021
- Sakigake Status Dropped for GSK’s Biliary Tract Cancer Drug
December 27, 2021
- Second Case of TTS with Possible Link to AstraZeneca COVID-19 Vaccine Reported in Japan
December 27, 2021
- Japan Does Not Recommend Ronapreve for Omicron Variant
December 27, 2021
- 145 Million Yen Allocated for 3 New Projects to Shake Off Public Distrust in Generics: MHLW FY2022 Budget
December 27, 2021
- Japan Secures 18 Million Extra Doses of Moderna Vaccines
December 27, 2021
- Japan Approves MSD’s Oral COVID-19 Drug Molnupiravir
December 27, 2021
- Regulatory Reform Panel Urges Better Trial Environment, SaMD Review
December 24, 2021
- MHLW to Set Up New Working Group to Discuss Technical Issues in Distribution: Ryukaikon
December 24, 2021
- New Generic Target Enshrined in Govt’s Updated Fiscal Reform Timeline
December 24, 2021
- Japan Panel OKs HPV “Catch-Up” Shots for Females Born in FY1997-FY2005
December 24, 2021
- Ronapreve Given to Nearly 37,000 People in Japan by November, Xevudy to 270: MHLW
December 24, 2021
- MHLW Eyes Information Provisioning on Generic Supplies by Individual Brands
December 24, 2021
- Japan to Revise PMD Law to Create Emergency Approval System, Final Paper Due Out by Year-End
December 23, 2021
- Chuikyo OKs FY2022 Drug Pricing Reform Outline; Spillover Exclusion, Mega Seller Rule
December 23, 2021
- Japan Seeks Additional Study for Aducanumab, Next Review Might Be Few Years Off
December 23, 2021
- Japan to Cut Drug Prices by 1.35% on Medical Cost Basis; No Special Rule for Adjustment Rate This Time
December 22, 2021
- AZ’s COVID-19 Drug to Be Reviewed with Priority if Filed in Japan: Senior Vice Minister
December 22, 2021
- Gist of FY2022 Drug Pricing Reform
December 22, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…